CA3217210A1 - Accelerated method of making lyophilized protein formualtions - Google Patents
Accelerated method of making lyophilized protein formualtions Download PDFInfo
- Publication number
- CA3217210A1 CA3217210A1 CA3217210A CA3217210A CA3217210A1 CA 3217210 A1 CA3217210 A1 CA 3217210A1 CA 3217210 A CA3217210 A CA 3217210A CA 3217210 A CA3217210 A CA 3217210A CA 3217210 A1 CA3217210 A1 CA 3217210A1
- Authority
- CA
- Canada
- Prior art keywords
- seq
- occurs
- mtorr
- ranging
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163195265P | 2021-06-01 | 2021-06-01 | |
| US63/195,265 | 2021-06-01 | ||
| PCT/US2022/031694 WO2022256359A1 (en) | 2021-06-01 | 2022-06-01 | Accelerated method of making lyophilized protein formualtions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3217210A1 true CA3217210A1 (en) | 2022-12-08 |
Family
ID=82100125
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3217210A Pending CA3217210A1 (en) | 2021-06-01 | 2022-06-01 | Accelerated method of making lyophilized protein formualtions |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240368254A1 (https=) |
| EP (1) | EP4346778A1 (https=) |
| JP (1) | JP2024521329A (https=) |
| KR (1) | KR20240016260A (https=) |
| CN (1) | CN117241787A (https=) |
| AR (1) | AR126044A1 (https=) |
| AU (1) | AU2022285665A1 (https=) |
| BR (1) | BR112023024757A2 (https=) |
| CA (1) | CA3217210A1 (https=) |
| CL (1) | CL2023003443A1 (https=) |
| IL (1) | IL307677A (https=) |
| MX (1) | MX2023014034A (https=) |
| TW (1) | TW202313108A (https=) |
| WO (1) | WO2022256359A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4553432B1 (en) | 2023-11-08 | 2026-04-29 | Bachem Holding AG | Drying bag and drying system |
| WO2025099273A1 (en) | 2023-11-08 | 2025-05-15 | Bachem Holding Ag | Drying bag and drying system |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| ATE243754T1 (de) | 1987-05-21 | 2003-07-15 | Micromet Ag | Multifunktionelle proteine mit vorbestimmter zielsetzung |
| EP1299419A2 (en) | 2000-05-24 | 2003-04-09 | Imclone Systems, Inc. | Bispecific immunoglobulin-like antigen binding proteins and method of production |
| JP2008512352A (ja) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | 新規な四価の二重特異性抗体 |
| CA2697922A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of igf-1r |
| IL272513B2 (en) * | 2017-09-15 | 2023-04-01 | Amgen Inc | Lyophilization process for pharmaceutical formulation of medical protein |
| AU2021330845A1 (en) * | 2020-08-24 | 2023-01-19 | Amgen Inc. | Pharmaceutical formulation comprising a bite, bispecific antibody, and methionine |
| KR20230067632A (ko) * | 2020-09-14 | 2023-05-16 | 암젠 인크 | 동결건조된 단백질 제형의 제조 방법 |
-
2022
- 2022-06-01 WO PCT/US2022/031694 patent/WO2022256359A1/en not_active Ceased
- 2022-06-01 AU AU2022285665A patent/AU2022285665A1/en active Pending
- 2022-06-01 MX MX2023014034A patent/MX2023014034A/es unknown
- 2022-06-01 KR KR1020237040273A patent/KR20240016260A/ko active Pending
- 2022-06-01 AR ARP220101446A patent/AR126044A1/es unknown
- 2022-06-01 CN CN202280030941.2A patent/CN117241787A/zh active Pending
- 2022-06-01 CA CA3217210A patent/CA3217210A1/en active Pending
- 2022-06-01 EP EP22731446.5A patent/EP4346778A1/en active Pending
- 2022-06-01 IL IL307677A patent/IL307677A/en unknown
- 2022-06-01 TW TW111120372A patent/TW202313108A/zh unknown
- 2022-06-01 US US18/561,081 patent/US20240368254A1/en active Pending
- 2022-06-01 BR BR112023024757A patent/BR112023024757A2/pt unknown
- 2022-06-01 JP JP2023573384A patent/JP2024521329A/ja active Pending
-
2023
- 2023-11-20 CL CL2023003443A patent/CL2023003443A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240016260A (ko) | 2024-02-06 |
| MX2023014034A (es) | 2023-12-15 |
| AU2022285665A1 (en) | 2023-10-19 |
| JP2024521329A (ja) | 2024-05-31 |
| TW202313108A (zh) | 2023-04-01 |
| US20240368254A1 (en) | 2024-11-07 |
| CL2023003443A1 (es) | 2024-06-14 |
| AR126044A1 (es) | 2023-09-06 |
| AU2022285665A9 (en) | 2023-10-26 |
| IL307677A (en) | 2023-12-01 |
| CN117241787A (zh) | 2023-12-15 |
| WO2022256359A1 (en) | 2022-12-08 |
| EP4346778A1 (en) | 2024-04-10 |
| BR112023024757A2 (pt) | 2024-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7676304B2 (ja) | 二特異性抗体の凝集を減少させるための方法 | |
| CN110418803A (zh) | 抗rsv单克隆抗体配制品 | |
| US20240368254A1 (en) | Accelerated method of making lyophilized protein formualtions | |
| US20230310324A1 (en) | Method of making lyophilized protein formulations | |
| US20230348596A1 (en) | Pharmaceutical formulation | |
| JP2026047374A (ja) | 医薬製剤 | |
| US20240316194A1 (en) | Method of reconstituting lyophilized formulation | |
| EA051496B1 (ru) | Ускоренный способ получения лиофилизированных белковых составов | |
| US20230167176A1 (en) | Pharmaceutical formulation | |
| AU2019351715C1 (en) | Methods for reducing aggregation of bispecific antibodies | |
| EA052508B1 (ru) | Фармацевтический состав, содержащий биспецифичное антитело bite и метионин |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250521 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250521 |